Department for Radiation Oncology and Diagnostics, Institute of Oncology and Radiology of Serbia, 11 000 Belgrade, Pasterova 14, Serbia.
J BUON. 2021 Mar-Apr;26(2):475-482.
Considering that cyclin D1 had a prognostic and clinical value for breast cancer patients, adequate measurement of cyclin D1 is necessary.
In this investigation, we detect cyclin D1 expression in tumour and peritumoral tissue of breast cancer patients by Western blotting method and by immunohistochemistry.
Cyclin D1 expression decreased significantly with each advanced clinical stage of disease and tumour size. Also, patients without lymph node involvement, with positive hormone receptors and Luminal A type of tumours had significantly increased the expression of cyclin D1. We show that cyclin D1 expression correlates with longer RFS in the entire group of patients, in the group of ER-positive and in the group of HER2-negative patients. Patients who were both ER and cyclin D1 positive had a better prognosis.
Taken together, our results, showing correlation of cyclin D1 with clinical stage, tumour size and lymph nodes, suggest that cyclin D1 expression, detected by Western blotting, could be considered as an additional marker for the staging of breast cancer, as well as a marker for longer RFS and survival in ER-positive breast cancer patients.
鉴于细胞周期蛋白 D1 对乳腺癌患者具有预后和临床价值，因此需要对其进行充分的测量。
在本研究中，我们通过 Western blot 法和免疫组织化学法检测乳腺癌患者肿瘤和肿瘤周围组织中细胞周期蛋白 D1 的表达。
细胞周期蛋白 D1 的表达随着疾病的临床分期和肿瘤大小的进展而显著降低。此外，无淋巴结受累、激素受体阳性和腔 A 型肿瘤的患者，细胞周期蛋白 D1 的表达明显增加。我们表明，细胞周期蛋白 D1 的表达与所有患者、ER 阳性患者和 HER2 阴性患者的 RFS 延长相关。同时，ER 和细胞周期蛋白 D1 均阳性的患者具有更好的预后。
综上所述，我们的结果表明细胞周期蛋白 D1 与临床分期、肿瘤大小和淋巴结相关，表明通过 Western blot 检测到的细胞周期蛋白 D1 表达可以被视为乳腺癌分期的附加标志物，以及 ER 阳性乳腺癌患者 RFS 和生存时间延长的标志物。
